ERYTech: Pfizer’s inotuzumab gets breakthrough therapy designation in ALL. Read-across for ErytechBUY, Fair Value EUR42 (+42%)
Pfizer announced it has received a Breakthrough Therapy Designation for inotuzumab ozogamicin following its phase III results as a monotherapy for adults suffering from ALL. We recognise that this antibody drug conjugate should be a new competitor for GRASPA, but we think the Street should not overestimate its ability to be a nuisance.
For more information, please contact firstname.lastname@example.org